The Journal of Immunology, Vol 153, Issue 2 499-506, Copyright © 1994 by American Association of Immunologists

ARTICLES

In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti-TNF, and anti-IFN-gamma antibodies

MH Bemelmans, D Abramowicz, DJ Gouma, M Goldman and WA Buurman
Department of Surgery, Faculty II, University of Limburg, Maastricht, The Netherlands.

Injection of anti-CD3 is accompanied by an increase in systemic TNF, a mediator of the physiologic changes induced by anti-CD3 injection. Various mechanisms have been reported to be responsible for TNF inactivation and clearance. Recently, it has become evident that circulating soluble TNFRs (P55 and P75), which are known to increase in response to TNF inducers such as LPS, represent a natural protection mechanism against circulating TNF. Here we show that triggering the TCR by anti-CD3 injection results in a strong induction of both systemic TNF and soluble TNFR release. Maximal levels of TNF were reached after 2 h (10 ng/ml). Maximum levels of P55 (450 pg/ml) were reached between 0.5 and 8 h, whereas the highest levels of P75 were reached after 2 h (28 ng/ml). Because TNF and IFN-gamma are supposed to be involved in the pathophysiology of the anti-CD3 response, we investigated the influence of in vivo neutralization of TNF and IFN-gamma. Injection of mAb to TNF and IFN-gamma significantly reduced systemic TNF levels and both soluble TNFR levels. Two inhibitors of anti-CD3 induced TNF release; steroids and pentoxifylline both reduced TNF levels and P75 levels without affecting P55 levels. The results show that T cell activation induces both systemic TNF release and release of both soluble TNFRs. Although TNF and IFN-gamma are involved in this mechanism, their role does not seem to be crucial.

This article has been cited by other articles:

				H. Zhang, N. Ameen, J. E. Melvin, and S. Vidyasagar Acute inflammation alters bicarbonate transport in mouse ileum J. Physiol., June 15, 2007; 581(3): 1221 - 1233. [Abstract] [Full Text] [PDF]

				L. Jin, D. P. Raymond, T. D. Crabtree, S. J. Pelletier, C. W. Houlgrave, T. L. Pruett, and R. G. Sawyer Enhanced Murine Macrophage TNF Receptor Shedding by Cytosine-Guanine Sequences in Oligodeoxynucleotides J. Immunol., November 1, 2000; 165(9): 5153 - 5160. [Abstract] [Full Text] [PDF]

				A. M. Jurewicz, A. K. Walczak, and K. W. Selmaj Shedding of TNF receptors in multiple sclerosis patients Neurology, October 22, 1999; 53(7): 1409 - 1409. [Abstract] [Full Text] [PDF]

				E. Quattrocchi, M. Walmsley, K. Browne, R. O. Williams, L. Marinova-Mutafchieva, W. Buurman, D. M. Butler, and M. Feldmann Paradoxical Effects of Adenovirus-Mediated Blockade of TNF Activity in Murine Collagen-Induced Arthritis J. Immunol., July 15, 1999; 163(2): 1000 - 1009. [Abstract] [Full Text] [PDF]

				N. S. Postma, R. C. Hermsen, D. J. A. Crommelin, W. M. C. Eling, and J. Zuidema Thiolated Recombinant Human Tumor Necrosis Factor-Alpha Protects against Plasmodium berghei K173-Induced Experimental Cerebral Malaria in Mice Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1027 - 1033. [Abstract] [Full Text]

				K. Hestdal, P. Aukrust, F. Muller, E. Lien, V. Bjerkeli, T. Espevik, and S. S. Froland Dysregulation of Membrane-Bound Tumor Necrosis Factor-alpha and Tumor Necrosis Factor Receptors on Mononuclear Cells in Human Immunodeficiency Virus Type 1 Infection: Low Percentage of p75-Tumor Necrosis Factor Receptor Positive Cells in Patients With Advanced Disease and High Viral Load Blood, October 1, 1997; 90(7): 2670 - 2679. [Abstract] [Full Text] [PDF]